sb.scorecardresearch
Advertisement
Republic Business
R.Bharat
Republic World
R.Bangla
R.Kannada
TRENDING/ Germany considering ways to support Volkswagen | X Brazil ban update | S&P 500, Dow Jones surge to record high |

Published 05:35 IST, September 20th 2024

Obesity drug developer BioAge seeks up to $587 milllion valuation in US IPO

Bioage's experimental drug, azelaprag, is being developed to treat obesity, in combination with GLP-1 agonists such as Eli Lilly's Zepbound and Novo Nordisk's Wegovy.

Reported by: Thomson Reuters
Follow: Google News Icon
  • share
BioAge Labs IPO
BioAge Labs IPO | Image: BioAge Labs
  • Listen to this article
  • 2 min read
Advertisement

05:35 IST, September 20th 2024